

Date: February 07, 2025

To,
The Deputy Gen. Manager,
Metropolitan Stock Exchange of India Ltd
Vibgyor Towers, 4th Floor, Plot No. C-62,
G-Block, Opp. Trident, Bandra-Kurla Complex,
Bandra (E), Mumbai-400 098

Dear Sir / Madam,

Sub: Outcome of Board Meeting of Jagadishwar Pharmaceutical Works Limited held on February 07, 2025

Ref: Regulation 33 (3) of SEBI (Listing Obligation and Disclosures Requirements) Regulations 2015

With reference to the above captioned subject, outcome of the meeting of the Board of Directors of Jagadishwar Pharmaceutical Works Limited which was held today at 04.00 p.m. and concluded at 04.30 p.m. is as follows:

Approved Unaudited Financial Results of the Company for the quarter ended December 31, 2024 were considered and approved by the Board.

Find enclosed herewith a copy of Unaudited Financial Results along with Limited Review Report pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.

You are requested to take note of the same.

Thanking You.

For Jagadishwar Pharmaceutical Works Limited

GUNODH Digitally signed by
GUNODHAR GHOSH
AR GHOSH Date: 2025.02.07
16:35:52 +05'30'

Gunodhar Ghosh
Executive Director
DIN : 08524622

Encl: As above

Jagadishwar Pharmaceutical Works Limited

(CIN : L24232AS1987PLC002803)

Regd Office: 205, Haribol Roy Market, A.T.Road, 2nd Floor, Near Saraf Building, Guwahati - 781 001

Corp. Office : 21/7, Sahapur Colony, Ground Floor, Kolkata – 700 053

Email: jpw ltd@yahoo.com, **Website:** jagadishwarpharma.com, **Tel.:** +91 9163513015

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2024

(Rs. In Lacs)


	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2024	30-09-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income From Operations						
	(a) Net Sales / Income from Operations (Net of Excise Duty)	-	-	-	-	-	-
	(b) Other Operating Income	6.568	5.992	7.366	18.755	22.340	29.520
	Total Income from Operations	6.568	5.992	7.366	18.755	22.340	29.520
2	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchase of stock-in-trade	7.250	-	-	7.250	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	7.250	-	-	7.250	-	-
	(d) Employee benefits expense	7.756	13.039	10.802	28.116	23.557	30.861
	(e) Depreciation and amortisation expense	-	-	-	-	-	0.057
	(f) Other expenses	0.931	1.119	1.580	6.456	8.972	9.930
	Total Expenses	8.688	14.158	12.381	34.572	32.529	40.848
3	Profit / (Loss) from Operations before other income, finance costs and exceptional items (1-2)	(2.120)	(8.166)	(5.015)	(15.817)	(10.189)	(11.328)
4	Other Income	-	-	-	-	-	-
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)	(2.120)	(8.166)	(5.015)	(15.817)	(10.189)	(11.328)
6	Finance Costs	-	-	-	-	-	-
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(2.120)	(8.166)	(5.015)	(15.817)	(10.189)	(11.328)
8	Exceptional Items	-	-	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7-8)	(2.120)	(8.166)	(5.015)	(15.817)	(10.189)	(11.328)
10	Tax Expense	0.647	0.599	0.728	1.865	2.225	0.002
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	(2.766)	(8.765)	(5.743)	(17.682)	(12.414)	(11.329)
12	Extraordinary item (net of tax Rs. Nil Lakhs)	-	-	-	-	-	-
13	Net Profit / (Loss) for the period (11-12)	(2.766)	(8.765)	(5.743)	(17.682)	(12.414)	(11.329)
14	Share of Profit / (loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13-14-15)	(2.766)	(8.765)	(5.743)	(17.682)	(12.414)	(11.329)
17	Other Comprehensive Income	-	-	-	-	-	14.876
18	Total Comprehensive Income	(2.766)	(8.765)	(5.743)	(17.682)	(12.414)	3.546
19	Paid-up Equity Share Capital (Face Value of Rs.10/- per Share)	2,970.019	2,970.019	2,970.019	2,970.019	2,970.019	2,970.019
20	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	135.405
21.i	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised)						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
21.ii	Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised)						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-

Notes:

- The above results have been reviewed by the audit committee and approved by the Board of Directors of the Company in its meeting held on 07/02/2025.
- The standalone financial results of the Company for the quarter and nine months ended 31st December, 2024 have been unaudited by the Statutory Auditors.
- Statutory Auditors have carried out a "Limited Review" of the above financial results for the quarter/nine months ended 31st December, 2024.
- Previous Period / Year figures have been regrouped/reclassified to make them comparable with those of current period/year.

For Jagadishwar Pharmaceutical Works Limited

Swapan
Kolkata
Swapan Sarkar
Director



Place : Kolkata
Date : 07/02/2025

(DIN: 05149442)



Review report to Jagadishwar Pharmaceutical Works Limited

We have reviewed the accompanying statement of unaudited financial results of Jagadishwar Pharmaceutical Works Limited (Name of the Company) for the period ended 31st December, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For **Rajesh U Shah & Associates**
Chartered Accountants



Rajesh Shah
Rajesh Shah

Proprietor

Membership Number: 056550

Firm Regn. No.: 327799E

UDIN: 25056550BMOLZT9165

Place: Kolkata

Date: February 7, 2025